enGene reports FY net loss of USD 117.3 million, more than double year-on-year

Reuters2025-12-23

enGene reports FY net loss of USD 117.3 million, more than double year-on-year

enGene Holdings Inc. reported its full year (FY) financial results for the period ended October 31, 2025. The company posted a net loss of USD 117.3 million for the year. Total operating expenses for the period were USD 123.2 million, including research and development expenses of USD 94.5 million and general and administrative expenses of USD 28.7 million. Net loss per share, basic and diluted, was USD 2.29. As of October 31, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities of USD 202.3 million. The weighted-average number of common shares outstanding, basic and diluted, was 51,119,479 for the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251222676164) on December 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593583784?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593583784","market":"fut","top_or_hot":-1,"title":"enGene reports FY net loss of USD 117.3 million, more than double year-on-year","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      enGene reports FY net loss of USD 117.3 million, more than double year-on-year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        enGene Holdings Inc. reported its full year (FY) financial results for the period ended October 31, 2025. The company posted a net loss of USD 117.3 million for the year. Total operating expenses for the period were USD 123.2 million, including research and development expenses of USD 94.5 million and general and administrative expenses of USD 28.7 million. Net loss per share, basic and diluted, was USD 2.29. As of October 31, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities of USD 202.3 million. The weighted-average number of common shares outstanding, basic and diluted, was 51,119,479 for the year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251222676164) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>enGene reports FY net loss of USD 117.3 million, more than double year-on-year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nenGene reports FY net loss of USD 117.3 million, more than double year-on-year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-23 05:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      enGene reports FY net loss of USD 117.3 million, more than double year-on-year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        enGene Holdings Inc. reported its full year (FY) financial results for the period ended October 31, 2025. The company posted a net loss of USD 117.3 million for the year. Total operating expenses for the period were USD 123.2 million, including research and development expenses of USD 94.5 million and general and administrative expenses of USD 28.7 million. Net loss per share, basic and diluted, was USD 2.29. As of October 31, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities of USD 202.3 million. The weighted-average number of common shares outstanding, basic and diluted, was 51,119,479 for the year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251222676164) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7QrwSq:1","article_id":"2593583784","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593583784","pubTimestamp":1766437403,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"enGene Holdings Inc. reported its full year  financial results for the period ended October 31, 2025. The company posted a net loss of USD 117.3 million for the year. Total operating expenses for the period were USD 123.2 million, including research and development expenses of USD 94.5 million and general and administrative expenses of USD 28.7 million. Net loss per share, basic and diluted, was USD 2.29. As of October 31, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities of USD 202.3 million. The weighted-average number of common shares outstanding, basic and diluted, was 51,119,479 for the year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENGN":"ENGENE HOLDINGS INC"},"translate_title":"enGene报告财年净亏损1.173亿美元，同比增长一倍多","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENGN":0.9},"content_text":"enGene reports FY net loss of USD 117.3 million, more than double year-on-year\n    \n\n        enGene Holdings Inc. reported its full year (FY) financial results for the period ended October 31, 2025. The company posted a net loss of USD 117.3 million for the year. Total operating expenses for the period were USD 123.2 million, including research and development expenses of USD 94.5 million and general and administrative expenses of USD 28.7 million. Net loss per share, basic and diluted, was USD 2.29. As of October 31, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities of USD 202.3 million. The weighted-average number of common shares outstanding, basic and diluted, was 51,119,479 for the year.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251222676164) on December 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593583784","isCrawlerRequest":true}